{"title": "PDF", "author": "PDF", "url": "www.unil.ch/webdav/site/fbm/shared/3_Romero_Suisse.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "du Gra nd-Es tG\u00e8nes codan de s lymphoc 1 Antigen di immunoth erapy coor dinator Pedro Romero (DCO I) Project 3 CS: Vaccination combined with ACT therap y following lymphodep letion SergeLeyvraz (CeP T cellresponses Nath alieRufer(NCCR-IS REC) Project 5 / CANV AC1. Antigen discover y and validation Focus on the identification an d experime ntal char acterizat ion of new colon canc er-assoc iated peptide a ntigens that could be used t o stimulat e tumor- react ive CTL precursors Two step approach: Identification of genes ov erexp ressed in colo rectal carci nom a (CRC) comp ared to healthy colon mucosa samp led from the sam e patients. Resu lts on CRC gene expression became recen tly availab le from a Massiv ely Parallel Signature Sequencing (MPSS) analysis p erformed in collaboration with the CRI an d Lynx Identify antigens using a n optimize d reverse imm unology approachfor tumor antigen ide ntification, de veloped llular anal ysis of T responses cancer patients under going ther apeuti c vaccination Stepwise optimization of mole cular ly defined v accines Phase I clinical trials in pat ients with metastatic me lanoma Monitoring with dire ct and quantitativ e T c ell assaysStepw ise vaccin e development (only one par ameter chang ed at the s ame time) Vaccines ba sed on Melan-A / MART-1 analog pepti de\"ELA\" : A.peptide Ag IFA depot/inflammation C.peptide + IFA + Cp G Ag depot/infl. + DC activation Endpoi nts: toxicity & CD 8 T cel l respons e Low doses: 0 .1 mg peptide, 0.3 ml IFA , 0.5 mg CpGRapid Ind uction of Melan- A Specific CD8 T Cell s in All Vaccina ted Patients% A2/Melan-A specif icT cells 0.010.1110 before 2 818 618 321 371 444 701 672PatientPF 676 + ELA + IFA ELA + IFA 0.1110 before 2 vacc 4 vacc4 431 446 460 481 470 567 444Patient without CpG 0.01 Mean \u00b1SD : Respond er patients:1.2 \u00b10.9 8 / 80.1 \u00b10.1 4 / 8Monitoring a CTL response to a well defined tumor antigen Enumeration and ph enotype by flow cytometry: TetramersPE, CD45RAAPC, secretion) ELISP OT Lytic ive hist ory: telomere length (F n-A speci fic \"EM\" T cell s N = na ive CM = central memory EM = effectormemory E = effectorNC M EM E CD45RA + - - + CCR7 + + - - LAU 627 <1 4 93 2 LAU 818 <1 7 89 3 LAU 618 <1 8 91 <1 LAU 321 5 30 60 5 LAU 371 <1 15 84 <1 LAU 444 1 1 93 5 LAU 701 2 5 62 31 LAU 672 5 7 86 3 mean 2 10 81 6 SD 2 10 13 94. Molecula r anal ysis of tumo r ant igen specific CD8 T onses in melan oma patients and trackin g of the dominant clones over time an d around the bod y compartments. Identifying TCRs u sed by potent tumor react ive, an tigen specificCD8 T cells. High a ffinity TCR ge ne transfer into pr imary CD8 and ents with strong naturally-aris ingimmune responses 2.Melanoma patients enrolled in peptide vaccinationclinical trials (Melan-A + IFA + CpG -oligodeoxynucleotide) and metastatic biopsies. 3.Melanoma patients enrolled in ACT followin g lymphodepletion clinical trials vaccine induc ed T cell respons e: Identification of ne w NC TNFdomain NC ACRP30 (serum protein) 0.10.30.5 0.01 10 /ml]Cell x3. Vaccination combined with therap y following lymphodepletion DAY -15 -13 -7 -6 - 5 -4 -3 -2 -1 0 1 15 30 45InclusionLympho pheresisRe- infusion (109cells) ineCan ant igen ltrialunderway,3 pat goal s of the Adoptive Cell Transfer Therap y project Continue to optimize in vitro expansion of antigen s pecific T lymphoc ytes Adapt the use of mod ified tetramers to minimize activation induced cell death up on sorti ng of spec ific T lymphoc ytes Explore the us e of d edicated immune gene arra y profiling to small numbers of pri mary antigen-specifi c T lymphoc ytes TCRs Desig n of peptide analogues w ith enhanced binding to the presen ting MHC molecules in c ycles of in silico molecular mo deling follo wedby wet bench testing of be st candida tes General methodolog y for TCR mode ling us ing ne wly generated algorithms and a bank of crystal structures TCRs f rom select ed high avidity and tumor reactive CT L clones from vaccinat ed pat ients will be modeled After cycles of in silico \u00ab affinity maturation \u00bb best fit candidates w ill be expressed as soluble heterodimers for BIACORE studies of binding kinetics to antigen clonin TCRs from me lanoma patients Expressio n vectors BIACORE studies Gene transfer into s ubpo pulations of CD8 and C D4 T cells in vitro Valid ation of redirected TCR g ene transfer in the HL A-A2 transgenic mice mo delPersp ectives: -CD4 T cel l help: Role of reg ulator y T cells in cancer, rol e of TG F-1 (in collabor ation oteins Recombin ant lentivector s -Monitorin g T cell function at tum or sites (in situ immunolog y) -H&NSCC (ORL) Integrated, multidis ciplina ry cancer immunothe rapy program interactions from ba sic immunolog y and bioinfor matics to clinics Lausanne Can cer Center International networking: joint immunomonitor ing studies with CANVAC Cancer Vaccine Co llaborative, Can cer Research Institute EUROV AC, FP6 IP Cancer Immunothe rapy...CANCEROPOL E DU G RAND EST "}